Indian Immunologicals Develops Intranasal COVID-19 Vaccine

Indian Immunologicals Ltd and Griffith University have developed a needle-free intranasal COVID-19 booster vaccine using codon deoptimization technology. This innovation aims to increase vaccination rates and enhance public health protection. COVID-19 continues to cause around 1,700 weekly deaths globally.

Indian Immunologicals Ltd on Tuesday announced the joint development of an intranasal COVID-19 vaccine.

The live-attenuated, needle-free booster vaccine was created in collaboration with Griffith University, Australia, utilizing codon deoptimization technology.

'This accomplishment signifies a major step forward in our battle against COVID-19. The development of this vaccine not only highlights our dedication to innovation in public health but also demonstrates the company's capability in adopting novel technology,' said IIL MD K Anand Kumar in a statement.

By offering non-invasive immunization, IIL aims to boost vaccination rates and safeguard more individuals and communities. According to the Hyderabad-based firm, COVID-19 remains a significant health issue, causing approximately 1,700 deaths per week globally.

(With inputs from agencies.)